Results 1 to 10 of about 37,178 (276)

Evaluation of CYP2C8 and CYP2C9 Polymorphisms in Neonates with Patent Ductus Arteriosus Treated with Ibuprofen or Indomethacin: A Retrospective Cohort Study [PDF]

Journal of Cardiovascular Development and Disease
The pharmacologic management of patent ductus arteriosus (PDA) presents a challenge to clinicians due to the interindividual variability in drug response to available medications.
Shaikha Jabor Alnaimi, Shimaa Aboelbaha, Ibrahim Safra, Mai Abdulla Al Qubaisi, Fouad Abounahia, Ahmed Al Farsi, Liji Cherian, Lizy Philip, Moza Alhail, Gulab Sher, Nader Al-Dewik   +10 more
doaj   +4 more sources

Comparison of CYP2C9 Activity in Ethiopian and Non-Ethiopian Jews Using Phenytoin as a Probe [PDF]

Frontiers in Pharmacology, 2020
The pharmacokinetics of CYP2C9 substrates is characterized by substantial interethnic variability. The objective of the study was to compare CYP2C9 activity by using Phenytoin Metabolic Ratio (PMR) between Ethiopian and non-Ethiopian Jews.
Zahi Abu Ghosh, Shoshana Alamia, Chanan Shaul, Yoseph Caraco   +3 more
doaj   +2 more sources

CYP2C9 polymorphisms are associated with phenytoin toxicity in South-Indian epileptic patients

Journal of Dr. NTR University of Health Sciences, 2020
Background and Aims: The contribution of CYP2C9 in phenytoin metabolism is generally modest, but it increases with increasing serum phenytoin concentration.
Rakesh Reddy Reddigari, S V Naveen Prasad, Vengamma Bhuma, P VGK Sarma, Appa Rao Anumolu   +4 more
doaj   +2 more sources

Human CYP2C9 Metabolism of Organophosphorus Pesticides and Nerve Agent Surrogates [PDF]

Journal of Xenobiotics
Of the Cytochrome P450 enzymes, the CYP2C9 variant is very important in the metabolism of several human drugs, acting as a natural bioscavenger. Previously, CYP2C9 was shown to convert the thion (P=S) to the oxon (P=O) form for some organophosphorus (OP)
Pratik Shriwas, Abigail M. Noonchester, Andre Revnew, Thomas R. Lane, Christopher M. Hadad, Sean Ekins, Craig A. McElroy   +6 more
doaj   +2 more sources

Characterisation of CYP2C8, CYP2C9 and CYP2C19 polymorphisms in a Ghanaian population [PDF]

BMC Medical Genetics, 2009
Background Genetic influences on drug efficacy and tolerability are now widely known. Pharmacogenetics has thus become an expanding field with great potential for improving drug efficacy and reducing toxicity.
Dodoo Alexander NO, Kudzi William, Mills Jeremy J   +2 more
doaj   +3 more sources

Associations of CYP2C9 and CYP2C19 Pharmacogenetic Variation with Phenytoin‐Induced Cutaneous Adverse Drug Reactions [PDF]

Clinical and Translational Science, 2020
The role of cytochrome P450 (CYP)2C9 and CYP2C19 genetic variation in risk for phenytoin‐induced cutaneous adverse drug events is not well understood independently of the human leukocyte antigen B (HLA‐B)*15:02 risk allele.
Alison E. Fohner, Allan E. Rettie, Khanh K. Thai, Dilrini K. Ranatunga, Brian L. Lawson, Vincent X. Liu, Catherine A. Schaefer   +6 more
doaj   +2 more sources

Polymorphisms of genes CYP2C9 and VKORC1 in patients with venous thromboembolic complications in Moscow population: effects on stability of anticoagulant therapy and frequency of hemorrhage

Терапевтический архив, 2011
Aim. To investigate frequency of carriage of genetic polymorphisms CYP2C9 and VKORC1 in patients with venous thromboembolic complications (VTEC) in Moscow population given warfarin treatment and effects of this carriage on stability of anticoagulation ...
Natal'ya Mikhaylovna Vorob'eva, Elizaveta Pavlovna Panchenko, Anatoliy Borisovich Dobrovol'skiy, Elena Vladimirovna Titaeva, Zukhra Bilyalovna Khasaeva, Nina Valer'evna Konovalova, Anton Yuvenal'evich Postnov, Aleksandr Ivanovich Kirienko, N M Vorobyeva, E P Panchenko, A B Dobrovolsky, E V Titaeva, Z B Khasaeva, N V Konovalova, A Yu Postnov, A I Kirienko   +15 more
doaj   +1 more source

Frequency of cytochrome P450 CYP2C9 variants in a Turkish population and functional relevance for phenytoin [PDF]

British Journal of Clinical Pharmacology, 1999
Jürgen Brockmöller, Muradiye Nacak, Ivar Roots   +2 more
exaly   +2 more sources

Impact of genetic and non-genetic factors on hepatic CYP2C9 expression and activity in Hungarian subjects

Scientific Reports, 2021
CYP2C9, one of the most abundant hepatic cytochrome P450 enzymes, is involved in metabolism of 15–20% of clinically important drugs (warfarin, sulfonylureas, phenytoin, non-steroid anti-inflammatory drugs).
Ferenc Fekete, Katalin Mangó, Máté Déri, Evelyn Incze, Annamária Minus, Katalin Monostory   +5 more
doaj   +1 more source

Clinical significance of the series of CYP2C9*non3 variants, an unignorable predictor of warfarin sensitivity in Chinese population

Frontiers in Cardiovascular Medicine, 2022
BackgroundsGene polymorphisms are critical for variations in warfarin dose. To date, more than 70 CYP2C9 alleles have been identified. This study was designed to clarify the clinical significance of CYP2C9*non-3 variants to warfarin sensitivity in ...
Dongxu Wang, Dongxu Wang, Hualan Wu, Min Dong, Qing Zhang, Anxu Zhao, Xinlong Zhao, Jia Chong, Minghui Du, Yan Wang, Haifeng Shi, Shuanghu Wang, Fang Wang, Jianping Cai, Jiefu Yang, Dapeng Dai, Hao Chen   +16 more
doaj   +1 more source